ArticleVirusdisease2025
Correlation of clinical, biochemical and molecular profile of dengue with disease severity.
Article in Virusdisease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The Indian subcontinent is endemic to dengue, with an estimated 33 million clinically apparent dengue cases annually, contributing to one-third of the total global dengue burden. This study aimed to assess the disease burden among dengue-suspected patients visiting our tertiary care center in North India and to explore the correlation between clinical-biochemical parameters in dengue fever or severe dengue with disease severity. Methods: A total of 318 dengue patients were enrolled in dengue fever with/without warning signs (DF ± WS, Results: The mean age was 36.02 ± 14.73 years and 35.46 ± 13.61 years for DF ± WS and SD individuals, respectively. Among DF ± WS patients, 49 (21.4%) were NS1 antigen positive, 122 (53.28%) had dengue IgM, and 58 (25.32%) were positive for both. In the severe dengue cohort, 14 (15.73%) and 45 (50.56%) were positive for NS1 and IgM, respectively, with 30 (33.71%) patients positive for both NS1 antigen and IgM antibodies. Among the DF ± WS and SD cohort, 35/229 (15.29%) and 31/79 (39.25%) patients had IgG antibodies depicting secondary dengue. The majority of patients were from Chandigarh ( Conclusion: Elevated liver function tests and severe thrombocytopenia in dengue patients indicate progression towards severe dengue with high mortality. A notable prevalence of secondary dengue infection (39.25%) was found in severe cases, with serotype-2 predominating in the north-Indian population. Supplementary Information: The online version contains supplementary material available at 10.1007/s13337-025-00930-0.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.